China Healthcare Weekly (Oct.13) - Deteriorating Financing Environment, ADC>BsAb>CGT, Fosun Pharma
⬇ $Shanghai Fosun Pharmaceutical (Group)(02196)$ - IPO policy change will worsen financing environment, putting PEVC in difficult position.For pharmaceutical hot field, the pecking order is ADC>BsAb>CGT.We analyzed key points of Fosun Pharma
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-oct-13-deteriorating-financing-environment-adc-bsab-cgt-fosun-pharma?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On Shanghai Fosun Pharmaceutical (Group) (02196):- https://www.smartkarma.com/entities/shanghai-fosun-pharmaceutical-group?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
